NICE recommends sparsentan for IgA nephropathy - PharmaTimes First non-immunosuppressive dual-action therapy approved for eligible patients

#renalmedicine #CSLVifor #nephrology #sparsentan #FILSPARI #IgAnephropathy #nonimmunosuppressivedualactiontherapy #NICE #NHS #primaryIgAnephropathy #PROTECTcliicaltrial #NICEguidance #IgAnephropathypatients #primaryglomerulardisease #kidneyfailure #Proteinuria
pharmatimes.com/news/nice-re...